Actos Lawsuit News: Federal Judge Overseeing Actos Bladder Cancer Litigation Schedules June Conferences, Bernstein Liebhard LLP Reports

The Firm is evaluating Actos lawsuits on behalf of patients who allegedly developed bladder cancer due to long-term use of the Type 2 diabetes drug.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
Free Case Review
“Our Firm continues to receive Actos lawsuit inquiries from individuals who allegedly developed bladder cancer due to long-term use of the Type 2 diabetes drug. We are pleased that these cases continue to move forward.

New York, New York (PRWEB) May 11, 2014

Thousands of Actos lawsuits (http://www.theactoslawsuitcenter.com/) that allege long-term use of the Type 2 diabetes drug caused patients to develop bladder cancer continue to move forward in a federal multidistrict litigation underway in U.S. District Court, Western District of Louisiana, Bernstein Liebhard LLP reports. According to an Order dated April 30th, U.S. District Judge Rebecca Doherty has scheduled the litigation’s next Status Conference for June 19, 2014. That same day, the Court will also convene a Pre-Trial Conference to facilitate and adjust the litigation’s Discovery Plan. (In re: Actos Product Liability Litigation, MDL No. 2299)

“Our Firm continues to receive Actos lawsuit inquiries from individuals who allegedly developed bladder cancer due to long-term use of the Type 2 diabetes drug. We are pleased that these cases continue to move forward,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to individuals who were treated with Actos for a year or more, and who allegedly went on to develop bladder cancer due to their use of the drug.

Actos Bladder Cancer Allegations
Court documents indicate that more than 3,000 Actos bladder cancer claims have been filed in courts around the country, the majority of which are pending in the Western District of Louisiana. The litigation concluded its first trial on April 7, 2014, with a jury rewarding the plaintiff $1.475 million in compensatory damages, along with $9 billion in punitive damages. (Allen v. Takeda Pharmaceuticals North America Inc., 12-cv-00064). All of the Actos lawsuits filed in the federal proceeding accuse Takeda Pharmaceuticals of failing to warn patients and doctors that extended use of Actos was associated with the development of bladder cancer.

According to court records, lawsuits involving Actos and bladder cancer began to mount shortly after the U.S. Food & Drug Administration (FDA) warned in June 2011 that use of the drug for more than a year was linked to a higher risk of bladder cancer. At the time, the FDA ordered Takeda Pharmaceuticals to add new information to the Warnings and Precautions section of the Actos label to reflect this risk.

Actos patients who allegedly developed bladder cancer due to long-term use of the medication may be entitled to compensation. To find out more about Actos lawsuits, please visit Bernstein Liebhard LLP’s website. For additional information, please call 800-511-5092 today.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com
http://www.theactoslawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author